Recently, mixed developments have been observed in the performance of Edwards Lifesciences Corp (EW). The stock has witnessed a number of downgrades from analysts, significantly bringing down its price target. The Q2 earnings have met the mark, despite experiencing a crash in margins. However, these results saw a dip in the company's stock value.
In addition, lowered guidance and a slower growth in the TAVR business have negatively impacted the company. Edwards Lifesciences also faced a substantial revenue miss contributing to its financial setbacks. The acquisition of Innovalve to enhance Transcatheter Mitral Valve Replacement (TMVR) solutions indicates EW's strategic moves towards business expansion.
Despite these obstacles, EW has managed to outperform its competitors on several trading days, showing its resilient market presence. Interestingly, the company is preparing to spin-off its critical care unit in 2024, marking a significant change in its business model. Furthermore, BD announced plans to acquire Edwards Lifesciences’ Critical Care business for $4.2B, signalling potential for future growth and diversification.
Edwards Lifesciences Corp EW News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sun, 28 Jul 2024 18:45:49 GMT - Rating -2 - Innovation 3 - Information 6 - Rumor 1
